NEW YORK— Genomic testing firm Veracyte reported after the close of the market on Thursday that its second quarter 2020 revenues fell 31 percent year over year on a sharp decline in testing revenues.
For the three months ended June 30, the South San Francisco, California-based molecular diagnostics firm reported total revenues of $20.7 million compared to $30.1 million in Q2 2019. It narrowly beat the analysts' average estimate of $20.6 million.